[
  {
    "ts": null,
    "headline": "REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors",
    "summary": "Glancy Prongay & Murray LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Radtke v. Regeneron...",
    "url": "https://finnhub.io/api/news?id=68fa61a9e6cf2c6e4777d2afa7bbd65752df3c9b9dda9d413a8dee2fe5d959da",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736287264,
      "headline": "REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors",
      "id": 132309581,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Glancy Prongay & Murray LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Radtke v. Regeneron...",
      "url": "https://finnhub.io/api/news?id=68fa61a9e6cf2c6e4777d2afa7bbd65752df3c9b9dda9d413a8dee2fe5d959da"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025",
    "summary": "TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of R",
    "url": "https://finnhub.io/api/news?id=42238dac1213f73d900d5d6d7bef7bbf19698a34e815912a63190fdb103b3d95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736283900,
      "headline": "Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025",
      "id": 132310971,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of R",
      "url": "https://finnhub.io/api/news?id=42238dac1213f73d900d5d6d7bef7bbf19698a34e815912a63190fdb103b3d95"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=4abe3a9ed6fa9a189804482fdfbac083d25912dc860d72fa1067c3b5b75d69f4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736268360,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 132327313,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=4abe3a9ed6fa9a189804482fdfbac083d25912dc860d72fa1067c3b5b75d69f4"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  }
]